Additional coverage of a report by OHSU's developing Gun Violence Prevention Research Center that found nonfatal gun injuries treated by emergency departments statewide have increased more dramatically than gun deaths in recent years.

Noreen Nazir, M.D., says it’s important to avoid or control high blood pressure, which increases the risk for heart attack, stroke and other conditions: “If you have risk factors you want to mitigate them. And if you have hypertension, you want to get it under control. You don’t want it to get worse.”

OHSU Doernbecher fetal surgeons Andrew Chon, M.D., and Raphael Sun, M.D., save twins facing life-threatening condition.

Pharmacy Times interviewed Richard Maziarz, M.D., regarding more effective graft-versus-host disease. Maziarz says: “If we can develop more effective GVHD prevention strategies, there should be real cost-savings to the health care system. This outcome would benefit individuals and health care systems financially while improving the quality of life for their patients."

Karen Gibbins, M.D., shares her personal story and calls on clinicians and hospitals to offer stillbirth evaluations, a systematic assessment that includes placental exams, genetic testing and autopsies.

Mark Flory, Ph.D., says technology from Seer makes it possible to uncover the vast complexity of the proteome at scale and quantify protein variants to study their role in health and diseases like cancer.

A Journal of General Internal Medicine perspective co-authored by Honora Englander, M.D., Ximena Levander, M.D., M.C.R., and Jessica Gregg, M.D., Ph.D., calls for a minimally disruptive approach that would create flexible, adaptive, context-sensitive, individualized, coherent and holistic treatment options for opioid use disorder.

Anti-animal research activists issue a press release critical of OHSU's use of animal models in some surgical training; OHSU provided the following statement ...

In a 2022 ASH meeting presentation, Rebecca Silbermann, M.D., discusses findings from the phase 2 GRIFFIN study, which evaluated therapy options for reducing pain symptoms for patients with transplant-eligible, newly diagnosed multiple myeloma. Silbermann says: “We had reductions in fatigue, meaningful reductions in pain, improvements in patient's overall assessment of their quality of life, and there was a signal that there was even better improvement in patient's symptoms for those who received daratumumab in combination with the lenalidomide, bortezomib, and dexamethasone."

In a 2022 ASH meeting presentation, Rebecca Silbermann, M.D., discusses findings from the phase 2 GRIFFIN study, which evaluated therapy options for reducing pain symptoms for patients with transplant-eligible, newly diagnosed multiple myeloma. Silbermann says: “We had reductions in fatigue, meaningful reductions in pain, improvements in patient's overall assessment of their quality of life, and there was a signal that there was even better improvement in patient's symptoms for those who received daratumumab in combination with the lenalidomide, bortezomib, and dexamethasone.